Reported September 29. 'FDA Grants First Marketing Authorization For A DNA Test To Assess Predisposition For Dozens Of Cancer Types'
Portfolio Pulse from Benzinga Newsdesk
The U.S. Food and Drug Administration (FDA) has granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, a DNA test that can detect genetic variants associated with an elevated risk of developing certain cancers. This is the first test of its kind to be granted FDA marketing authorization. The test evaluates DNA from a blood sample to identify variants in 47 genes known to be associated with an elevated risk of developing certain types of cancer.
October 02, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invitae's new DNA test, which has received FDA marketing authorization, could potentially increase the company's market share and revenues in the genetic testing industry.
The FDA's marketing authorization for Invitae's DNA test could potentially increase the company's visibility and credibility in the genetic testing industry. This could lead to increased sales and revenues for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100